Program
nilotinib
Also written as “Nilotinib”, “AMN107” and “Tasigna”.
Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Gastrointestinal Stromal Tumors · Neoplasms · Leukemia, Myeloid, Chronic-Phase · Leukemia, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 541 open or running | phase 4since Sep 19, 2008 | May 2, 2005 | Aug 30, 2030phase 4 · NCT04877522 |
| Xspray Pharma AB | 20 open or running | phase 1since Jul 29, 2025 | Jul 29, 2025 | none ahead |
| XSpray Microparticles | 10 open or running | phase 1since Feb 19, 2014 | Feb 19, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 41 studies since May 2, 2005.
- Nov 14, 2012Phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT01735955 · 57 enrolled · United States, Austria, Canada and more
- Dec 4, 2012Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT01743989 · 620 enrolled · Austria, Belgium, Bulgaria and more
- Dec 5, 2012Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT01744665 · 59 enrolled · United States
- Jan 30, 2013Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT01784068 · 215 enrolled · United States, Argentina, Austria and more
- Apr 29, 2013Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT01844765 · 59 enrolled · United States, France, Hungary and more
- May 23, 2013Phase 2 study in Gastrointestinal Stromal TumorsNovartis · NCT01863745 · 15 enrolled · Japan
- Feb 19, 2014XSpray Microparticles's first study: phase 1 study in HealthyNew to XSpray MicroparticlesXSpray Microparticles · NCT02068898 · 27 enrolled · United Kingdom
- Apr 7, 20142 phase 3 studiesNovartis · NCT02108951, NCT02115386
- Sep 17, 2014Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT02253277 · 5 enrolled · Germany
- Oct 21, 2014Phase 3 study in LeukemiaNovartis · NCT02272777 · 225 enrolled · China
- Sep 9, 2015Phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT02546674 · 171 enrolled · Germany
- Mar 5, 2019Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT03874858 · 135 enrolled · Italy
- May 4, 2021Phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT04877522 · 347 planned · United States, Argentina, Austria and more
- Jul 29, 2025Xspray Pharma AB's first studies: 2 phase 1 studies in NeoplasmsNew to Xspray Pharma ABXspray Pharma AB · NCT07138378, NCT07138352
Ahead
- Aug 30, 2030Primary completion: phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT04877522
TargetBeta
“Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| imatinibrule | Novartis | phase 4 | 70 |
| asciminibrule | Novartis | phase 4 | 16 |
| olverembatinibrule | Ascentage Pharma Group International | phase 3 | 10 |
| Embibatinib | Hansoh Pharmaceutical Group | phase 3 | 7 |
| TQB3911 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 57 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07138378Neoplasms · India | 1 | Completed | Xspray Pharma AB | Dec 15, 2024 | 128 |
| NCT07138352Neoplasms · United States | 1 | Completed | Xspray Pharma AB | Jan 8, 2025 | 48 |
| NCT04877522Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Austria and more | 4 | Recruiting | Novartis | Aug 30, 2030 | 347 |
| NCT03874858Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Italy | 2 | Terminated | Novartis | Oct 15, 2025 | 135 |
| NCT02546674Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany | 4 | Completed | Novartis | Feb 23, 2021 | 171 |
| NCT02272777Leukemia · China | 3 | Completed | Novartis | Jan 30, 2017 | 225 |
| NCT02253277Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany | 1 | Completed | Novartis | Mar 6, 2018 | 5 |
| NCT02115386Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Russian Federation | 3 | Terminated | Novartis | Oct 31, 2016 | 7 |
| NCT02108951Leukemia · Australia | 3 | Terminated | Novartis | Aug 10, 2016 | 20 |
| NCT02068898Healthy · United Kingdom | 1 | Completed | XSpray Microparticles | Mar 2014 | 27 |
| NCT01863745Gastrointestinal Stromal Tumors · Japan | 2 | Completed | Novartis | Oct 2, 2023 | 15 |
| NCT01844765Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, France, Hungary and more | 2 | Completed | Novartis | Jun 1, 2016 | 59 |
| NCT01784068Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Austria and more | 2 | Completed | Novartis | May 31, 2016 | 215 |
| NCT01744665Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States | 2 | Completed | Novartis | Sep 28, 2018 | 59 |
| NCT01743989Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Austria, Belgium, Bulgaria and more | 3 | Completed | Novartis | Jul 8, 2020 | 620 |
| NCT01735955Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Austria, Canada and more | 4 | Completed | Novartis | Jul 7, 2023 | 57 |
| NCT01698905Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Australia and more | 2 | Completed | Novartis | Nov 26, 2015 | 163 |
| NCT01605981Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Brazil | 4 | Withdrawn | Novartis | Jan 2017 | 0 |
| NCT01368523Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Poland | 4 | Completed | Novartis | Jan 2010 | 19 |
| NCT01289028Gastrointestinal Stromal Tumors · Germany, Italy | 3 | Completed | Novartis | Jul 2014 | 125 |
| NCT01275196Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China | 3 | Completed | Novartis | Oct 2014 | 267 |
| NCT01274351Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Turkey | 2 | Completed | Novartis | Aug 1, 2019 | 112 |
| NCT01279473Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Japan | 2 | Completed | Novartis | Dec 2009 | 42 |
| NCT01254188Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Algeria, Argentina, Australia and more | 3 | Completed | Novartis | Nov 2014 | 421 |
| NCT01227577Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States | 4 | Completed | Novartis | Nov 2014 | 128 |
| NCT01223898Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany, United Kingdom | 1 | Completed | Novartis | Dec 2013 | 19 |
| NCT01220648Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany | 1 | Completed | Novartis | Jan 2014 | 4 |
| NCT01206088CML · Korea, Republic of | 4 | Completed | Novartis | Sep 2012 | 93 |
| NCT01179737Pulmonary Arterial Hypertension · United States, Canada, Germany and more | 2 | Terminated | Novartis | Jan 2013 | 23 |
| NCT01131325Leukemia, Myeloid, Chronic-Phase · United States | 4 | Terminated | Novartis | May 12, 2011 | 3 |
| NCT01126892Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Colombia, Venezuela | 3 | Completed | Novartis | Apr 2011 | 6 |
| NCT01110668Gastrointestinal Stromal Tumors · Turkey | 2 | Completed | Novartis | Sep 2011 | 2 |
| NCT01077544Leukemia, Myelogenous, Chronic, BCR-ABL Positive · France, Italy, Netherlands and more | 1 | Completed | Novartis | Jul 1, 2015 | 15 |
| NCT01061177Leukemia · Austria, Belgium, Bulgaria and more | 4 | Completed | Novartis | Jul 2014 | 1,090 |
| NCT01043874Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Japan | 4 | Completed | Novartis | Dec 2013 | 45 |
| NCT01028222Melanoma · United States, Argentina, Australia and more | 2 | Completed | Novartis | Dec 2014 | 55 |
| NCT00980018Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada | 4 | Completed | Novartis | Dec 2012 | 52 |
| NCT00802841Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Argentina, Brazil, China and more | 3 | Completed | Novartis | Jul 2014 | 191 |
| NCT00786812Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Brazil | 4 | Completed | Novartis | Jan 2012 | 89 |
| NCT00785785Gastrointestinal Stromal Tumors · United States, Argentina, Austria and more | 3 | Completed | Novartis | Oct 2014 | 644 |
| NCT00760877Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Argentina, Australia, Brazil and more | 3 | Completed | Novartis | Jul 2015 | 207 |
| NCT00756509Gastrointestinal Stromal Tumors · Finland, France, Germany and more | 4 | Completed | Novartis | Dec 18, 2024 | 34 |
| NCT00751036Gastrointestinal Stromal Tumors · Argentina, Brazil, Canada and more | 3 | Terminated | Novartis | Aug 2012 | 94 |
| NCT00718562Gastrointestinal Stromal Tumors · Japan | 2 | Completed | Novartis | Jul 2013 | 35 |
| NCT00644878Leukemia, Myeloid, Chronic-Phase · United States | 2 | Terminated | Novartis | Mar 2012 | 18 |
| NCT00633295Gastrointestinal Stromal Tumors · Israel | 2 | Completed | Novartis | May 2010 | 9 |
| NCT00519090Leukemia, Myeloid · United States, Australia, Belgium and more | 3 | Terminated | Novartis | Oct 2008 | 6 |
| NCT00471497Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Austria and more | 3 | Completed | Novartis | Sep 2, 2009 | 846 |
| NCT00471328Gastrointestinal Stromal Tumors · United States, Australia, Austria and more | 3 | Completed | Novartis | Aug 2008 | 248 |
| NCT00441155Gastrointestinal Stromal Tumors · United States, France, Italy | 1 | Completed | Novartis | Jan 2011 | 14 |
| NCT00418769Healthy | 1 | Completed | Novartis | Aug 2006 | 24 |
| NCT00418756Healthy | 1 | Completed | Novartis | Nov 2006 | 12 |
| NCT00418626Healthy · United States | 1 | Completed | Novartis | Sep 2007 | 27 |
| NCT00384228Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Japan | 2 | Completed | Novartis | Jan 2007 | 42 |
| NCT00264160Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Israel | 3 | Completed | Novartis | Nov 2008 | 36 |
| NCT00135005Gastrointestinal Stromal Tumors · United States, France, Germany and more | 1 | Completed | Novartis | Nov 2006 | 59 |
| NCT00109707Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Austria and more | 2 | Completed | Novartis | Sep 2012 | 507 |
How it is read
Names in the registry
- “Nilotinib”, 35 entries
- “nilotinib”, 9 entries
- “AMN107”, 3 entries
- “Tasigna”, 2 entries
- “Nilotinib (AMN107)”, 2 entries
Codes read as this program: XS003.
Conditions, from the studies’ own filings
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 34 studies
- Gastrointestinal Stromal Tumors, 11 studies
- Neoplasms, 2 studies
- Leukemia, Myeloid, Chronic-Phase, 1 study
- Leukemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.